Mir-302 Reprograms Human Skin Cancer Cells into a Pluripotent ES-cell-like State
Overview
Authors
Affiliations
Renewal of stem cells differs from cancer cell growth in self-controlled cell division. The mir-302 microRNA (miRNA) family (mir-302s) is expressed most abundantly in slow-growing human embryonic stem (ES) cells, and quickly decreases after cell differentiation and proliferation. Therefore, mir-302s was investigated as one of the key factors essential for maintenance of ES cell renewal and pluripotency in this study. The Pol-II-based intronic miRNA expression system was used to transgenically transfect the mir-302s into several human cancer cell lines. The mir-302-transfected cells, namely, miRNA-induced pluripotent stem (mirPS) cells, not only expressed many key ES cell markers, such as Oct3/4, SSEA-3, SSEA-4 ,Sox2, and Nanog, but also had a highly demethylated genome similar to a reprogrammed zygotic genome. Microarray analyses further revealed that genome-wide gene expression patterns between the mirPS and human ES H1 and H9 cells shared over 86% similarity. Using molecular guidance in vitro, these mirPS cells could differentiate into distinct tissue cell types, such as neuron-, chondrocyte-, fibroblast-, and spermatogonia-like primordial cells. Based on these findings, we conclude that mir-302s not only function to reprogram cancer cells into an ES-like pluripotent state but also to maintain this state under a feeder-free cultural condition, which may offer a great opportunity for therapeutic intervention.
CHIR99021 and Brdu Are Critical in Chicken iPSC Reprogramming via Small-Molecule Screening.
Jin K, Zhou J, Wu G, Li Z, Zhu X, Liang Y Genes (Basel). 2024; 15(9).
PMID: 39336797 PMC: 11431361. DOI: 10.3390/genes15091206.
Tumor Microenvironment Modulation by Cancer-Derived Extracellular Vesicles.
Ten A, Kumeiko V, Farniev V, Gao H, Shevtsov M Cells. 2024; 13(8.
PMID: 38667297 PMC: 11049026. DOI: 10.3390/cells13080682.
Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine.
Inagaki M J Dev Biol. 2024; 12(1).
PMID: 38535481 PMC: 10971469. DOI: 10.3390/jdb12010001.
Marks M, Gimenez C, Isaja L, Vera M, Borzone F, Pereyra-Bonnet F J Cancer Res Clin Oncol. 2024; 150(2):106.
PMID: 38418798 PMC: 10902018. DOI: 10.1007/s00432-024-05607-7.
Pensotti A, Bizzarri M, Bertolaso M Oncol Rep. 2024; 51(3).
PMID: 38275101 PMC: 10835663. DOI: 10.3892/or.2024.8707.